Sep 14, 2018, 01:00 by admin admin

Sep 14, 2018, 01:00 by admin admin

ASAM led a letter sent to House leadership expressing concerns with the finalized version of the American Health Care Act (AHCA). The letter was signed by 435 organizations representing consumers, families, providers, health care and social service professionals, advocates and allied organizations who are committed to meaningful and comprehensive policies to reduce the toll of substance use disorders and mental illness through prevention, treatment and recovery support services.

Sep 14, 2018, 01:00 by admin admin

ASAM joined 20 other organizations in sending a letter to Congressional leadership urging action on finding a bipartisan solution to ensure continued full funding of cost-sharing reduction payments (CSRs) to qualified health plans for eligible enrollees who have coverage through the exchanges.

Sep 14, 2018, 01:00 by admin admin

The U.S. Senate confirmed Dr. Elinore McCance-Katz as the first Assistant Secretary for Mental Health and Substance Use. The American Society of Addiction Medicine (ASAM) applauds the Senate for approving Dr. McCance-Katz’s nomination and congratulates Dr. McCance-Katz on her new role.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments to the House Committee on Energy and Commerce offering recommendations to build on the Comprehensive Addiction and Recovery Act (CARA) and 21st Century CURES Act. The recommendations included growing the treatment workforce, increasing education for opioid prescribers, and improving access to overdose treatment and treatment for pregnant and postpartum women.

Sep 14, 2018, 01:00 by admin admin

ASAM led a coalition letter signed by 468 other organizing expressing serious concerns with several of the health system reform included in the Graham-Cassidy-Heller-Johnson (GCHJ) proposal. The letter highlights how GCHJ’s proposed changes to our health care system would result in reductions in health care coverage, particularly for individuals with substance use disorders and mental illness, and we cannot support the bill.

Sep 14, 2018, 01:00 by admin admin

Sep 14, 2018, 01:00 by admin admin

ASAM sent a letter to  on April 3 to Dr. Tom Price, the Secretary of the Department of Heath and Human Services, to express support for Dr. Elinor McCance-Katz for the position of Assistant Secretary for Mental Health and Substance Use.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with a recommended revision for A4910 and S3272, legislation that would align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.

Sep 14, 2018, 01:00 by admin admin

On December 30, 2017, the Food and Drug Administration (FDA) announced the approval of Sublocade, a monthly formulation of buprenorphine subcutaneous injection for treatment of opioid dependence. This injection is the first monthly formulation of buprenorphine to be approved by the FDA.

Sep 14, 2018, 01:00 by admin admin

ASAM led a coalition letter signed by 465 organizations sharing serious concerns regarding the Better Care Reconciliation Act (BCRA). The letter emphasized how the BCRA’s proposed changes to the health care system will result in reductions in health care coverage, particularly for vulnerable populations including those suffering from substance use disorders and mental illness.

Sep 14, 2018, 01:00 by admin admin

ASAM joined a coalition letter expressing support for the Bipartisan Health Care Stabilization Act of 2017 and leading bipartisan efforts to provide stabilization to the health insurance marketplace. 

Sep 14, 2018, 01:00 by admin admin

The statement includes recommendations to support correctional policy makers and correctional healthcare professionals in providing evidence-based care to those in their custody or under their supervision who have an opioid use disorder.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted two comment letters to the Food and Drug Administration (FDA) regarding new subcutaneous injectable buprenorphine formulations. In the letters, ASAM reiterated support for new pharmacotherapies for addiction and that patients should have a robust and varied array of treatment options. The letters also highlighted that these new formulations of would be injected one or twice monthly and have the potential to decrease diversion.

Sep 14, 2018, 01:00 by admin admin

ASAM led a letter signed by 432 health organizations sharing concerns with the most recent version of the American Health Care Act (AHCA).

Sep 14, 2018, 01:00 by admin admin

ASAM signed onto a letter led by the Ohio Society of Addiction Medicine (OHSAM), along with several other Ohio health care groups. The letter urged the Ohio Department of Medicaid (ODM) to require Medicaid managed care plans to use nationally recognized clinical standards, such as ASAM’s, when determining coverage standards for substance use disorder services.

Sep 14, 2018, 01:00 by admin admin

On behalf of the Mental Health Liaison Group (MHLG), we are writing to express our opposition of specific provisions within the House and Senate versions of the Tax Cuts and Jobs Act, particularly the provisions repealing the Affordable Care Act’s individual shared responsibility mandate and the House’s provision repealing the medical expense deduction. 

Sep 14, 2018, 01:00 by admin admin

ASAM and the Partnership to Amend 42 CFR Part 2 (Partnership) sent a letter strongly supporting the Overdose Prevention and Patient Safety (OPPS) Act, H.R. 3545, which would align 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of health care treatment, payment, and operations (TPO).

Sep 14, 2018, 01:00 by admin admin

Sep 14, 2018, 01:00 by admin admin

This Policy Statement includes recommendations on standards related to the marketing of addiction treatment services and recruiting of patients as well as state and federal government development and dissemination of materials for consumers to detect potential fraudulent marketing and patient recruiting practices.